# Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers

> **NCT06531512** · PHASE2,PHASE3 · RECRUITING · sponsor: **Oneness Biotech Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DRUG:** Xianglei Tangzu Gao
- **OTHER:** Vehicle Cream

## Key facts

- **NCT ID:** NCT06531512
- **Lead sponsor:** Oneness Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-16
- **Primary completion:** 2025-12
- **Final completion:** 2026-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06531512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06531512, "Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06531512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*